{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:15:17Z","timestamp":1795032917848,"version":"4.10.2"},"reference-count":16,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T00:00:00Z","timestamp":1227484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p><jats:bold>Aim:\u2002<\/jats:bold> The present study was a 52\u2010week, non\u2010comparative, open\u2010label study of flexible dose paroxetine (20\u201340\u2003mg) in 52 Japanese post\u2010traumatic stress disorder (PTSD) patients in order to obtain clinical experience regarding efficacy and safety in regular clinical practice.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> Efficacy was measured using the Clinician\u2010Administered PTSD Scale One Week Symptom Status Version (CAPS\u2010SX).<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The mean change from baseline in CAPS\u2010SX total score was \u221219.1, \u221222.8 and \u221232.3 at weeks 4, 12 and 52, respectively, and that in the Clinical Global Impression (CGI) Severity of Illness score was \u22121.1 at week 12 and \u22121.7 at week 52. A total of 46.9% were CGI responders at week 12, while 67.3% were improved on the CGI at week 52. Of 52 subjects who entered into the drug treatment, 25 completed the study. Only one patient withdrew from the study due to lack of efficacy. In patients who were rated as \u2018moderately ill\u2019 or less at baseline, the proportion of CGI responders at end\u2010point was higher at a dose of 20\u2003mg\/day than at higher doses, whereas in patients rated as \u2018markedly ill\u2019 or more, it was higher at 30 and 40\u2003mg\/day, suggesting that severely ill patients could benefit from higher doses.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> Paroxetine appeared generally tolerated in short\u2010 and long\u2010term use, and the safety profile in this study was consistent with international trials and other Japanese populations (i.e. patients suffering from depression, panic disorder or obsessive\u2013compulsive disorder). Although the study was not conducted in double\u2010blind fashion, the current findings suggest that paroxetine may contribute to clinically meaningful improvement that is maintained during long\u2010term use and is generally well tolerated.<\/jats:p>","DOI":"10.1111\/j.1440-1819.2008.01862.x","type":"journal-article","created":{"date-parts":[[2008,11,24]],"date-time":"2008-11-24T08:55:14Z","timestamp":1227516914000},"page":"646-652","source":"Crossref","is-referenced-by-count":18,"title":["Clinical evaluation of paroxetine in post\u2010traumatic stress disorder (PTSD): 52\u2010week, non\u2010comparative open\u2010label study for clinical use experience"],"prefix":"10.1111","volume":"62","author":[{"given":"Yoshiharu","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomu","family":"Asukai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Hirotsune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyasu","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,11,24]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994"},{"key":"e_1_2_6_3_2","first-page":"147","volume-title":"PTSD Brain Mechanisms and Clinical Implications","author":"Kim Y","year":"2007"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000291650.70816.D6"},{"issue":"16","key":"e_1_2_6_5_2","first-page":"1","article-title":"The Expert Consensus Guideline Series: Treatment of posttraumatic stress disorder","volume":"60","author":"Foa EB","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_6_6_2","first-page":"35","article-title":"Diagnosis, treatment, and efficacy of early intervention for PTSD","volume":"29","author":"Asukai N","year":"2000","journal-title":"Jpn. J. Clin. Psychiatry"},{"issue":"5","key":"e_1_2_6_7_2","first-page":"60","article-title":"Consensus statement on posttraumatic stress disorder from the International Consensus Group on depression and anxiety","volume":"61","author":"Ballenger JC","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199206004-00005"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v62n1105"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.1.36"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.12.1982"},{"key":"e_1_2_6_12_2","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E8) General Considerations For Clinical Trials 1997. Available from URL:http:\/\/www.pmda.go.jp\/"},{"key":"e_1_2_6_13_2","unstructured":"Ministry of Health Labour and Welfare (MHLW) Guideline for Clinical Evaluation of Anxiolytics 1988 Iyaku\u2010shin 1 (7)."},{"key":"e_1_2_6_14_2","unstructured":"International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH E9) Statistical Principles For Clinical Trials 1998. Available from URL:http:\/\/www.pmda.go.jp\/"},{"key":"e_1_2_6_15_2","first-page":"187","article-title":"Clinical evaluation of paroxetine HCL, a selective serotonin reuptake inhibitor, in the treatment of depression of depressive episodes: Double blind, parallel group study with amitriptyline HCl","volume":"28","author":"Miura S","year":"2000","journal-title":"Jpn. Pharmacol. Ther."},{"key":"e_1_2_6_16_2","first-page":"295","article-title":"Clinical evaluation of paroxetine HCL, a selective serotonin reuptake inhibitor, in the treatment of panic disorder","volume":"28","author":"Tsutsui S","year":"2000","journal-title":"Jpn. Pharmacol. Ther."},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2004.01278.x"}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-1819.2008.01862.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-1819.2008.01862.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T12:16:49Z","timestamp":1696940209000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-1819.2008.01862.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,24]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1111\/j.1440-1819.2008.01862.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-1819.2008.01862.x","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,24]]}}}